Synonyms: Altrenogest ; 850-52-2 ;steroid powder CAS No.: 850-52-2 Formula: C21H26O2 Molecular Weight: 310.47 EINECS: 212-703-1 Density: 1.15 g/cm3 Boiling Point: 495.6 °C at 760 mmHg Flash Point: 210.1 °C Storage: store in cool, dry, ventilated place Packing: 1kg/aluminum foil bag Min. order quantity: 10g Payment: Western Union, Moneygram Shipment: EMS, DHL, FedEx, TNT Delivery: safe & timely, around 7days after payment.
Product Description Altrenogest(A35957; RU2267) is a progestogen structurally related to veterinary steroid trenbolone. Altrenogest is a synthetic trienic C21 steroidal progestomimetic, belonging to the 19-nor-testosterone series. It is an orally active (pro)gestagen. Like all steroids, altrenogest acts by its liposolubility by penetrating the target cells where it binds to specific receptors. In veterinary medicine, altrenogest is used in gilts and mares for zootechnical purposes (oestrus synchronization).
Altrenogest also known as allyltrenbolone or allyltrienolone, as well as 17α - allyl - 19- nor - δ9,11-testosterone or 17α - allylestra -4,9,11- trien -17β - ol - 3- one, is a steroidal progestin of the 19-nortestosterone and allyltestosterone groups related to allylestrenol, norgestrienone, and trenbolone that is widely used in veterinary medicine to suppress or synchronize estrus in horses and pigs. It is available for veterinary use in both Europe and the United States and has been marketed as Regumate since the early 1980s.
Altrenogest is an estrane ( C18 ) steroid and 19 - nortestosterone derivative known chemically as 17α - allyl -19- nor - δ9,11- testosterone or 17α - allylestra -4,9,11- trien -17β - ol -3- one. It is one of only two marketed progestins that possesses a 17α - allyl group, the other being allylestrenol. Most other progestins possess a 17α - ethynyl group, while AAS, if they are 17α - substituted, are usually 17α - alkylated ( with a methyl or ethyl group ). Altrenogest is the 17α - allylated derivative of the AAS trenbolone (and hence can also be referred to as allyltrenbolone or allyltrienolone ), which itself is the 9,11- didehydro analogue of the AAS nandrolone ( 19 - nortestosterone ).
The pharmacodynamic activity of altrenogest has been demonstrated in a number of animal models. The most important effects are the progestomimetic and anti-gonadotrophic effects. Altrenogest also has weak oestrogenic, anabolic and androgenic effects, but has no corticoid or anti-inflammatory effects.
Altrenogest is indicated to suppress estrus in mares to allow a more predictable occurrence of estrus following withdrawal of the drug.
It is used clinically to assist mares to establish normal cycles during the transitional period from anestrus to the normal breeding season often in conjunction with an artificial photoperiod. It is more effective in assisting in pregnancy attainment later in the transition period. One group of authors ( Squires et al. 1983 ) suggest selecting mares with considerable follicular activity (mares with one or more follicles 20 mm or greater in size ) for treatment during the transitional phase. Mares that have been in estrus for 10 days or more and have active ovaries are also considered to be excellent candidates for progestin treatment.
Altrenogest is effective in normally cycling mares for minimizing the necessity for estrus detection, for the synchronization of estrus and permitting scheduled breeding.
Estrus will ensue 2-5 days after treatment is completed and most mares ovulate between 8-15 days after withdrawal. Altrenogest is also effective in suppressing estrus expression in show mares or mares to be raced. Although the drug is labeled as contraindicated during pregnancy, it has been demonstrated to maintain pregnancy in oophorectomized mares and may be of benefit in mares who abort due to sub-therapeutic progestin levels.